E Fund Management Co. Ltd. Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY

E Fund Management Co. Ltd. purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 6,073 shares of the biopharmaceutical company’s stock, valued at approximately $1,828,000.

Several other hedge funds have also recently modified their holdings of ALNY. Asahi Life Asset Management CO. LTD. acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $418,000. Shepherd Financial Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $825,000. West Family Investments Inc. purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter worth $231,000. NewEdge Wealth LLC purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter worth $2,738,000. Finally, Danske Bank A S acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $19,433,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling

In other news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ALNY shares. Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 2nd. Barclays decreased their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. Oppenheimer dropped their price objective on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. BMO Capital Markets started coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday. They issued an “outperform” rating and a $318.00 price objective on the stock. Finally, Citigroup reduced their target price on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a report on Monday, August 3rd. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $386.62.

Alnylam Pharmaceuticals Trading Up 6.1%

Shares of ALNY stock opened at $242.61 on Thursday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $197.81 and a 1-year high of $495.55. The company has a market cap of $32.46 billion, a price-to-earnings ratio of 45.09 and a beta of 0.30. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The stock has a 50 day simple moving average of $269.15 and a 200-day simple moving average of $298.51.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same period in the previous year, the business earned ($0.51) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 66.9% on a year-over-year basis. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.